Search

Displaying results 4901 - 4910 of 10000 in total
  1. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

  2. Drug

    Carmofur

    go.drugbank.com/drugs/DB09010
    ApprovedWithdrawn

    Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.

  3. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. … It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  4. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). … [A265125,L46762] It is an allogeneic encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor

    Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid, Allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid encoding human ciliary neurotrophic factor (CNTF).
  5. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist … It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated.

  6. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    By reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.

  7. Drug

    MT-0169

    go.drugbank.com/drugs/DB17430
    Investigational

    MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.

  8. Drug

    C11-12 isoparaffin

    go.drugbank.com/drugs/DB11329
    Approved

    C11-12 isoparaffin is a mixture of branched chain hydrocarbons with 11C or 12C's in the alkyl chain. It is found in cosmetic and personal care products as solvents or skin conditioning agent.

  9. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.

  10. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]